Bottom line
How much do PPH and IHE overlap?
43% of their top holdings overlap by weight. 11 securities appear in both funds' top 25, making up 48.5% of PPH's assets and 73.4% of IHE's. They share a meaningful core but differ in the rest of the portfolio.
IHE holds far more positions (59 vs 26), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings PPH and IHE have in common
| Holding | % of PPH | % of IHE | Overlap |
|---|---|---|---|
| Eli Lilly & Co | 20.23% | 22.25% | 20.23% |
| Merck & Co Inc | 9.85% | 4.55% | 4.55% |
| Pfizer Inc | 4.51% | 3.96% | 3.96% |
| Bristol-Myers Squibb Co | 4.47% | 4.37% | 4.37% |
| Johnson & Johnson | 4.35% | 22.44% | 4.35% |
| Zoetis Inc | 2.10% | 3.73% | 2.10% |
| Viatris Inc | 1.10% | 4.22% | 1.10% |
| Axsome Therapeutics Inc | 0.77% | 2.42% | 0.77% |
| Corcept Therapeutics Inc | 0.50% | 1.90% | 0.50% |
| Elanco Animal Health Inc | 0.35% | 2.81% | 0.35% |
| Organon & Co | 0.23% | 0.81% | 0.23% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in PPH
- Novartis AG — 10.63%
- Novo Nordisk A/S — 5.37%
- AbbVie Inc — 4.57%
- Gsk Plc — 4.42%
- AstraZeneca PLC — 4.33%
- McKesson Corp — 4.12%
- Sanofi SA — 4.00%
- Cencora Inc — 3.36%
- Haleon PLC — 3.09%
- Teva Pharmaceutical Industries Ltd — 3.06%
- Takeda Pharmaceutical Co Ltd — 2.87%
- Jazz Pharmaceuticals PLC — 1.08%
- State Street Global Advisors — 0.28%
- Bausch Health Cos Inc — 0.10%
Only in IHE
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 6.24%
- Royalty Pharma Plc — 4.34%
- Jazz Pharmaceuticals Public Limited Company — 3.45%
- Ligand Pharmaceuticals Incorporated — 1.45%
- Definium Therapeutics Inc — 1.39%
- Liquidia Corp — 1.28%
- Indivior Pharmaceuticals, Inc. — 1.14%
- Crinetics Pharmaceuticals Inc — 0.90%
- Edgewise Therapeutics Inc — 0.70%
- Amneal Pharmaceuticals, Inc. — 0.68%
- Enliven Therapeutics Inc — 0.63%
- Supernus Pharmaceuticals, Inc. — 0.62%
- Tarsus Pharmaceuticals Inc — 0.57%
- Veradermics Inc — 0.56%
Asset mix
| Asset type | PPH | IHE |
|---|---|---|
| Stocks | 99.5% | 99.9% |
| Cash & short-term funds | 0.3% | 6.3% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Country mix
| Country | PPH | IHE |
|---|---|---|
| US | 60.8% | 96.4% |
| GB | 11.8% | 4.3% |
| CH | 10.6% | — |
| DK | 5.4% | — |
| FR | 4.0% | — |
| IE | 1.1% | 3.8% |
| IL | 3.1% | — |
| JP | 2.9% | — |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Check another pair
FAQ
How much do PPH and IHE overlap?
What stocks do PPH and IHE have in common?
Should I own both PPH and IHE?
Which holds more stocks, PPH or IHE?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.